Biocon Biologics receives FDA approval for biosimilar YESAFILI, the first in the US ophthalmology market.
Biocon Biologics has received U.S. FDA approval for its biosimilar YESAFILI, marking its entry into the US ophthalmology market. The company, which also received approvals in Europe and the UK, is the first to obtain FDA approval for a biosimilar aflibercept. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor used to treat ophthalmological conditions such as neovascular age-related macular degeneration, visual impairment due to macular oedema, diabetic macular oedema, and visual impairment due to myopic choroidal neovascularisation.
May 20, 2024
10 Articles